Naif S Sannan1, Cheryl Y Gregory-Evans1, Christopher J Lyons2, Anna M Lehman3, Sylvie Langlois3, Simon J Warner1, Helen Zakrzewski4, Kevin Gregory-Evans5. 1. Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, B.C. 2. Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, B.C; Department of Ophthalmology, BC Children's Hospital, Vancouver, B.C. 3. Department of Medical Genetics, University of British Columbia, Vancouver, B.C. 4. Cumming School of Medicine, University of Calgary, Calgary, Alta. 5. Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, B.C. Electronic address: kge30@mail.ubc.ca.
Abstract
OBJECTIVE: To describe the clinical presentation and genotype of subjects with aniridia with a particular focus on foveal hypoplasia. DESIGN: Prospective cohort study. PARTICIPANTS: Thirty-three Canadian participants with aniridia and of various ethnic backgrounds residing in British Columbia. METHODS: Full ophthalmic examinations and posterior segment spectral domain-optical coherence tomography (SD-OCT) imaging were performed. Foveal hypoplasia was graded independently by 2 staff ophthalmologists. PAX6 sequencing was performed and chromosomal 11p anomalies investigated. Candidate gene and single-nucleotide polymorphism sequencing in genes functionally related to PAX6 were also studied. RESULTS: Best corrected visual acuities in the cohort ranged from 0.0 logMAR to no light perception. Total absence of iris tissue was seen in the majority (42 of 66 eyes). In those in whom SD-OCT was possible, foveal hypoplasia was seen in the majority (45 of 56 eyes, 80%). Molecular genetic defects involving PAX6 were identified in 30 participants (91%), including 4 novel PAX6 mutations (Gly18Val; Ser65ProfsX14; Met337ArgfsX18; Ser321CysfsX34) and 4 novel chromosome 11p deletions inclusive of PAX6 or a known PAX6 regulatory region. CONCLUSIONS: The number of PAX6 mutations associated with aniridia continues to increase. Variable foveal architecture despite nearly identical anterior segment disease in 4 participants with an Ex9 ELP4-Ex4 DCDC1 deletion suggested that molecular cues causing variation in disease in the posterior segment differ from those at play in the anterior segment. Results in 3 patients without identifiable PAX6 mutations and a review of the literature suggest that such cases be described as phenocopies rather than actual cases of the syndrome of aniridia.
OBJECTIVE: To describe the clinical presentation and genotype of subjects with aniridia with a particular focus on foveal hypoplasia. DESIGN: Prospective cohort study. PARTICIPANTS: Thirty-three Canadian participants with aniridia and of various ethnic backgrounds residing in British Columbia. METHODS: Full ophthalmic examinations and posterior segment spectral domain-optical coherence tomography (SD-OCT) imaging were performed. Foveal hypoplasia was graded independently by 2 staff ophthalmologists. PAX6 sequencing was performed and chromosomal 11p anomalies investigated. Candidate gene and single-nucleotide polymorphism sequencing in genes functionally related to PAX6 were also studied. RESULTS: Best corrected visual acuities in the cohort ranged from 0.0 logMAR to no light perception. Total absence of iris tissue was seen in the majority (42 of 66 eyes). In those in whom SD-OCT was possible, foveal hypoplasia was seen in the majority (45 of 56 eyes, 80%). Molecular genetic defects involving PAX6 were identified in 30 participants (91%), including 4 novel PAX6 mutations (Gly18Val; Ser65ProfsX14; Met337ArgfsX18; Ser321CysfsX34) and 4 novel chromosome 11p deletions inclusive of PAX6 or a known PAX6 regulatory region. CONCLUSIONS: The number of PAX6 mutations associated with aniridia continues to increase. Variable foveal architecture despite nearly identical anterior segment disease in 4 participants with an Ex9 ELP4-Ex4 DCDC1 deletion suggested that molecular cues causing variation in disease in the posterior segment differ from those at play in the anterior segment. Results in 3 patients without identifiable PAX6 mutations and a review of the literature suggest that such cases be described as phenocopies rather than actual cases of the syndrome of aniridia.
Authors: Hilde R Pedersen; Maureen Neitz; Stuart J Gilson; Erlend C S Landsend; Øygunn Aas Utheim; Tor Paaske Utheim; Rigmor C Baraas Journal: Ophthalmol Retina Date: 2019-02-05
Authors: James D Cole; Kara M McHaney; Behnam Rabiee; Jingyi Gao; Carlos Rodriguez; David A Miller; Mingna Liu; Marta Grannonico; Pedro Norat; Hao F Zhang; Ali R Djalilian; Xiaorong Liu Journal: Exp Eye Res Date: 2022-03-01 Impact factor: 3.770
Authors: Helen J Kuht; Gail D E Maconachie; Jinu Han; Line Kessel; Maria M van Genderen; Rebecca J McLean; Michael Hisaund; Zhanhan Tu; Richard W Hertle; Karen Gronskov; Dayong Bai; Aihua Wei; Wei Li; Yonghong Jiao; Vasily Smirnov; Jae-Hwan Choi; Martin D Tobin; Viral Sheth; Ravi Purohit; Basu Dawar; Ayesha Girach; Sasha Strul; Laura May; Fred K Chen; Rachael C Heath Jeffery; Abdullah Aamir; Ronaldo Sano; Jing Jin; Brian P Brooks; Susanne Kohl; Benoit Arveiler; Lluis Montoliu; Elizabeth C Engle; Frank A Proudlock; Garima Nishad; Prateek Pani; Girish Varma; Irene Gottlob; Mervyn G Thomas Journal: Ophthalmology Date: 2022-02-11 Impact factor: 14.277
Authors: Anna Voskresenskaya; Nadezhda Pozdeyeva; Yevgeniy Batkov; Tatyana Vasilyeva; Andrey Marakhonov; Richard A West; Jeffrey L Caplan; Ales Cvekl; Yan Wang; Melinda K Duncan Journal: Exp Eye Res Date: 2020-11-26 Impact factor: 3.467
Authors: Kevin Yongblah; Spencer C Alford; Bridget C Ryan; Robert L Chow; Perry L Howard Journal: Mol Ther Nucleic Acids Date: 2018-09-01 Impact factor: 8.886
Authors: Jack W Hickmott; Uvini Gunawardane; Kimberly Jensen; Andrea J Korecki; Elizabeth M Simpson Journal: Gene Ther Date: 2018-09-26 Impact factor: 5.250